US20110275535A1 - Yeast Display Systems - Google Patents

Yeast Display Systems Download PDF

Info

Publication number
US20110275535A1
US20110275535A1 US13/139,332 US200913139332A US2011275535A1 US 20110275535 A1 US20110275535 A1 US 20110275535A1 US 200913139332 A US200913139332 A US 200913139332A US 2011275535 A1 US2011275535 A1 US 2011275535A1
Authority
US
United States
Prior art keywords
canceled
molecule
display
binding site
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/139,332
Other languages
English (en)
Inventor
Andreas Loew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115977&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110275535(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to US13/139,332 priority Critical patent/US20110275535A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOEW, ANDREAS
Publication of US20110275535A1 publication Critical patent/US20110275535A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Definitions

  • the present invention relates to the field of protein display libraries and library screening. More specifically, the present invention relates to the production of proteins for display on cell surfaces.
  • Protein binding domains can be predicted from sequence data, however re-designing proteins with improved or altered binding affinities often requires testing of a number of variants of the re-designed protein.
  • the best method for obtaining proteins with desired binding affinities is to generate and screen a protein library including such variants that can include rationally redesigned proteins, randomly altered proteins, or a combination thereof.
  • Libraries of many types of protein, such as immunoglobulins and scaffold proteins and receptors or receptor ligands have successfully been constructed and screened for binding affinity.
  • phage display method which comprises fusion of a protein library to the coat proteins of filamentous phage e.g.,(Huse et al., '89; Clackson et al,, '91); Marks et al., '92). Fusions are made most commonly to a minor coat protein, called the gene III protein (pIII), which is present in three to the copies at the tip of the phage.
  • the fused library is then displayed on the surface of the viral particle.
  • the pap display library can then be screened against an immobilized target protein.
  • target proteins that bind the library with very high affinity are not always identified because the conditions required to elute the bound phase usually denature the phage particle such that it becomes impossible to identify the protein of interest.
  • Another draw back of phage display libraries is the requirement that the target protein be immobilized on a solid surface, which can lead to difficulties in determining the actual affinity of a target protein for the phage display protein.
  • some proteins of interest require post-translational modifications, such as glycosylation, methylation, or disulfide binding, that cannot be achieved when expressed in a phage particle.
  • An alternative method for screening protein libraries is to display the library on the surface of bacterial cells. This method solves many of the drawbacks associated with phage display but has its own problems.
  • One problem with bacterial display is that the bacterial capsule can cause steric hindrance to proteins displayed on the bacterial surface.
  • bacteria do not contain the machinery to properly fold eukaryotic proteins, so the protein of interest may not always be expressed within the bacterium. Similar to the problem in phage, bacteria cannot provide post-translational modifications, like disulfide binding, to a eukaryotic protein.
  • Wittrup et al. (U.S. Pat. Nos. 6,699,558 and 5,696,251) have developed a method for a yeast cell display library.
  • This is a two component system, wherein the first component involves expressing one subunit of the yeast mating adhesion protein, agglutinin, which is anchored to the yeast cell wall.
  • the second component involves expressing a protein library fused to a second subunit of the agglutinin protein which forms high affinity disulfide bonds to the first agglutinin subunit.
  • the protein library fused to the agglutinin is thus displayed on the surface of the cell.
  • the library can then be screened. This method allows for the proper folding and post-translational modification of eukaryotic proteins.
  • Rakestraw et al. have developed a three component system for displaying a protein library on the surface of yeast cells.
  • the first component involves expressing a protein library fused to a biotin-binding peptide
  • the second component involves modifying the yeast cell wall to express biotin
  • the third component involves binding avidin to the biotin expressed on the cell surface.
  • the fused protein library is then biotinylated and secreted from the yeast cell and binds to the avidin on the yeast cell surface, thus displaying the protein library on the surface of the yeast cell.
  • avidin non-specifically binds all biotin.
  • avidin contains four binding sites, which may cause steric hindrance thus preventing the biotinylated protein library from binding to the cell surface bound avidin.
  • the avidin molecule may bind the biotin) fated protein library before binding the biotinylated yeast cell wall, thereby hindering the binding of the avidin to the yeast cell wall.
  • this method contains the added complication of having to biotinylate the protein library within the yeast cell. This necessary extra step requires further modification to the yeast cell. It is well established that the more modifications are made to a biological system, the less likely it is that the system will behave as designed.
  • biotin/streptavidin and biotin/avidin are used in a number of commercially available labeling kits. Such kits would be difficult to use in such a biotin/avidin display system.
  • the prior art lacks a simple, efficient system capable of specifically binding a secreted protein library using an adapter molecule that binds to the protein library and to the surface of a eukaryotic cell through different binding moieties.
  • One aspect includes host cells with a cell surface molecule attached to the surface of the cell, an adapter molecule comprising a first binding site and a second binding site and a display molecule comprising a modified polypeptide where the first binding site binds specifically to the cell surface molecule and cannot bind to the display molecule, the second binding site binds specifically to the display molecule and cannot bind to the cell surface molecule, and adapter molecule is not a component of the modified polypeptide.
  • the host cell has a plurality of display molecules.
  • the host cell surface molecule may be covalently linked to the first binding, site.
  • the host cell surface molecule may be covalently linked to the first binding site through a disulfide bond.
  • the host cell surface molecule may include a first agglutinin which may be Aga1p.
  • the host cell surface molecule may be attached to the cell membrane via at GPI anchor.
  • the first binding site comprises a second agglutinin which may be Aga2p.
  • the second binding site may be covalently linked to the display molecule. In other embodiments which may be combined with any of the preceding embodiments, the second binding site may be covalently linked to the display molecule through disulfide bonds. In other embodiments which may be combined with any of the preceding embodiments, the second binding site includes a PDZ domain which may be the PDZ domain of InaD which may have the amino acid sequence of SEQ ID NO: 8. In other embodiments which may be combined with any of the preceding embodiments, the display molecule includes a NorpA ligand which may be at the C-terminus which may have the amino acid sequence of SEQ ID NO: 9.
  • the display molecule includes a PDZ domain which may be the PDZ domain of InaD which may have the amino acid sequence of SEQ ID NO: 8.
  • the second binding site includes a PDZ domain or where the display molecule comprises a NorpA ligand
  • the second binding site includes a NorpA ligand which may be at the C-terminus which may have the amino acid sequence or SEQ ID NO: 9.
  • the modified polypeptide may be a scaffold protein, a signal transduction protein, an antibody, an immunoglobulin, an immunoadhesin, a receptor, a ligand an oncoprotein, a transcription factor, or an enzyme.
  • display molecule may be a fibronectin polypeptide which may include an F10 polypeptide.
  • the display molecule includes a secretion signal peptide may be an MFalpha, secretion signal sequence, a glucoamylase, an Aga2 secretion signal sequence, an Flo1p secretion signal sequence, an invertase secretion signal sequence, or an acid phosphatase secretion signal sequence.
  • the secretion signal peptide may be an MFalpha/HSA hybrid leader peptide.
  • expression of the display molecule is under the control of a first inducible promoter which may be an AOX 1 promoter, a Cup 1 promoter, or a Gal promotor.
  • expression of the adapter molecule is under the control of a second inducible promoter which may be an AOX 1 promoter, a Cup 1 promoter, or a Gal promotor
  • the host cell may be a yeast cell which may Pichia pastoris or Saccharomyces cerevisiae.
  • Another aspect includes libraries of host cells which include least two host cells in accordance with the preceding aspect and any and all of its embodiments where each host cell includes a different modified polypeptide.
  • Yet another aspect includes methods for displaying a modified polypeptide which includes (a) providing a host cell comprising a cell surface molecule attached to the surface of the cell and a first nucleic acid encoding a display polypeptide comprising a modified polypeptide, (b) contacting the host cell with an adapter molecule comprising a first binding site and a second binding site under conditions wherein the first binding site binds to the cell surface molecule, and then (c) incubating, the host cell under conditions wherein the host cell exports the display polypeptide outside the host cell under conditions wherein the second binding site binds to the display polypeptide, where the first binding site binds specifically to the cell surface molecule and cannot bind to the display molecule, the second binding site binds specifically to the display polypeptide and cannot hind to the cell surface molecule, and the adapter molecule is not a component of the modified polypeptide.
  • the host cell may display at least 10 2 , at least 10 3 , at least 10 4 , or at least 10 5 modified polypeptides.
  • the host cell surface molecule may be covalently linked to the first binding site.
  • the host cell surface molecule may be covalently linked to the first binding site through a disulfide bond.
  • the host cell surface molecule may include a first agglutinin which may be Aga1p.
  • the host cell surface molecule may be attached to the cell membrane via a GPI anchor.
  • the first binding site comprises a second agglutinin which may be Aga2p.
  • the second binding site may be covalently linked to the display molecule.
  • the second binding site may be covalently linked to the display molecule through disulfide bonds.
  • the second binding site includes a PDZ domain which may be the PDZ domain of InaD which may have the amino acid sequence of SEQ ID NO: 8.
  • the display molecule includes a NorpA ligand which may heat the C-terminus which may have the amino acid sequence of SEQ ID NO: 9.
  • the display molecule includes a PDL domain which may be the PDZ domain of InaD which may have the amino acid sequence of SEQ ID NO: 8.
  • the second binding site includes a PDZ domain or where the display molecule comprises a NorpA ligand
  • the second binding site includes a NorpA ligand which may be at the C-terminus which may have the amino acid sequence of SEQ ID NO: 9.
  • the modified polypeptide may be a scaffold protein, a signal transduction protein, an antibody, an immunoglobulin, an immunoadhesin, a receptor, a ligand, an oncoprotein, a transcription factor, or an enzyme.
  • display molecule may be a fibronectin polypeptide which may include an F10 polypeptide.
  • the display molecule includes a secretion signal peptide may be an MFalpha secretion signal sequence, a glucoamylase an Aga2 secretion signal sequence, an Flo1p secretion signal sequence, an invertase secretion signal sequence, or an acid phosphatase secretion signal sequence.
  • the secretion signal peptide may be an MFalpha/HSA hybrid leader peptide.
  • expression of the display molecule is under the control of a first inducible promoter which may be an AOX 1 promoter, a Cup 1 promoter, or a Gal promotor.
  • expression of the adapter molecule is under the control of a second inducible promoter which may be an AOX 1 promoter, a Cup 1 promoter, or a Gal promotor.
  • the host cell may be a yeast cell winch may be Pichia pastoris or Saccharomyces cerevisiae.
  • Still another aspect includes methods for generating a host cell display library which includes introducing into a plurality of host cells a display library of first nucleic acids each encoding a display polypeptide comprising a modified polypeptide, wherein at least two of the introduced first nucleic acids encode different modified polypeptides, wherein each host cell comprises a second nucleic acid which encodes a cell surface polypeptide and a third nucleic acid which encodes an adapter molecule comprising a first binding site and a second binding site where the first binding site binds to the cell surface molecule but not the display polypeptide, the second binding site binds to the display polypeptide but not the cell surface molecule, and the adapter molecule is not as component of the modified polypeptide.
  • This aspect may be combined with any of the embodiments of the preceding aspects.
  • FIG. 1 shows a schematic of the three component system including the cell surface molecule, the adapter molecule including the first and second binding sites and the display molecule with the binding partner for the second binding site (a binding polypeptide in this embodiment) and a modified polypeptide as the molecule being displayed.
  • the host cell is a yeast cell.
  • FIG. 2 shows the pPlC3.5 AGA1 vector for yeast expression of the Aga1p as the cell surface molecule.
  • FIG. 3 shows the pPlC6 A AGA2-InaD vector for yeast expression of the Aga2p-InaD fusion polypeptide as the adapter molecule.
  • FIG. 4 shows the pPlCHOLl-1 MFalpha1 Hsa-Fn10-NorpA vector for yeast expression of the MFalpha1Hsa-Fn10-NorpA fusion polypeptide as the display molecule where the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the fibronectin F10 domain is modified polypeptide.
  • the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the fibronectin F10 domain is modified polypeptide.
  • FIG. 5 shows the pPlCHOL1-C MFalpha1 Hsa-Fn10-NorpA vector for yeast expression of the MFalpha1Hsa-Fn10-NorpA fusion polypeptide as the display molecule where the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the fibronectin HO domain is modified polypeptide.
  • the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the fibronectin HO domain is modified polypeptide.
  • FIG. 6 shows the pYD NBC1 Aga2-InaD vector for yeast expression of the Aga2p-InaD fusion polypeptide as the adapter molecule.
  • FIG. 7 shows the pYS HSA MFalpha1 Fn10 NorpA vector for yeast expression of the MFalpha1HSA-Fn10-NorpA fusion polypeptide a the display molecule where the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the fibronectin F10 domain is modified polypeptide.
  • the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the fibronectin F10 domain is modified polypeptide.
  • FIG. 8 shows the pYS MFalpha1 HSA NorpA vector for yeast expression of the MFalpha1-HSA-NorpA fusion polypeptide as the display molecule where the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the HSA is the displayed polypeptide.
  • the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the HSA is the displayed polypeptide.
  • FIG. 9A-E are FACS analysis graphs showing protein surface expression of yeast cells expressing either fibronectin (pYS6/CT HSA MFalpha1 Fn10 NorpA) or HSA (pYS6/CT MFalpha1-HSA-NorpA) in which the yeast cells are stained with anti-myc antibody and APC labeled secondary anti-mouse antibody.
  • FIG. 9A is the a control with unstained yeast cells:
  • FIG. 9B are uninduced yeast cells expressing fibronectin;
  • FIG. 9C are induced yeast cells expressing fibronectin showing a shift in the curve;
  • FIG. 9D are uninduced yeast cells expressing HSA; and
  • FIG. 9E are induced yeast cells expressing HSA showing a shift in the curve.
  • FIG. 10A-E are images of FMAT analysis of yeast cells expressing either fibronectin (pYS6/CT HSA MFalpha1 Fn 10 NorpA) or HSA (pYS6/CT HSA-NorpA) in which the yeast cells are stained with anti-myc mouse monoclonal antibody and APC labeled secondary anti-mouse antibody and subjected to FMAT confocal fluorescence.
  • FIG. 10A is the a control with unstained yeast cells: FIG. 10B are uninduced yeast cells expressing fibronectin; FIG. 10C are induced yeast cells expressing fibronectin appearing as white spots; FIG. 101 ) are uninduced yeast cells expressing HSA; and FIG. 10E are induced yeast cells expressing HSA appearing, as white spots.
  • FIG. 11 shows the pYS MFalpha1 scFv lysozyme NorpA vector for yeast expression attic MFalpha1 scFv lysozyme NorpA fusion polypeptide as the display molecule where the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the lysozyme is modified polypeptide.
  • the NorpA is the binding partner of the second binding site of the adapter molecule (i.e., InaD) and the lysozyme is modified polypeptide.
  • FIG. 12 shows a reversed system in which the pYD NBC1 Aga2-NorpA vector is used for yeast expression of the NBC1 Aga2-NorpA,
  • FIG. 13 shows a reversed system in which the pYS6/CT*MFalpha1-InaD-Fn10 vector is used for yeast expression of the MFalpha1-InaD-Fn10.
  • the term “host cell” refers to a eukaryotic cell that has been modified to express a cell surface molecule, an adapter molecule, and a display molecule. Furthermore, it should be understood that the host cell secretes or excretes the display molecule prior to binding the display molecule to the adapter molecule on the surface of the host cell.
  • cell surface molecule refers to a peptide, polypeptide, binding domain, ligand, lipid, or carbohydrate that is directed to the extracellular surface of the host cell.
  • the cell surface molecule may be anchored to the cell surface by covalent binding or non-covalent binding.
  • the cell surface molecule may include a phospholipid, carbohydrate or protein through which it attaches to the surface of the host cell.
  • the cell surface molecule may be a polypeptide that binds to, or is conjugated to a phospholipid, carbohydrate, or a polypeptide on the surface of the cell.
  • the polypeptide may use a phosphatidyl-inositol-glycan (GPI) anchor to attach to the surface of the host cell, such as ⁇ -agglutinins, ⁇ -agglutinins, and flocculins.
  • the cell surface molecule may also be a transmembrane protein with a binding domain located on the surface of the host cell that can bind to the first binding site of the adapter molecule.
  • the term “adapter molecule” refers to a peptide, polypeptide, binding domain, ligand, lipid, or carbohydrate or combination of the foregoing that has two distinct binding sites.
  • the adapter molecule has a binding site that specifically binds the cell surface molecule and a second distinct binding she that specifically binds the display molecule.
  • the two binding sites of the polypeptide ma bi polypeptide domains each with its on binding affinity to a different molecule that are fused together.
  • the polypeptide may be an a-agglutinin subunit, such as Aga2p, fused to a PDZ domain, or it may be a flocculin, such as Flo1, fused to a PDZ domain.
  • a-agglutinin subunit such as Aga2p
  • flocculin such as Flo1
  • the term “first binding site” refers to a region of the adapter molecule that specifically recognizes and binds at least a portion of the cell surface molecule.
  • the first binding site may comprise a peptide, polypeptide, binding domain, ligand, lipid, or carbohydrate or combination thereof that specifically binds to a cell surface molecule which could include, without limitation, a peptide, binding domain, ligand, protein, lipoprotein, lipid, or carbohydrate. More specifically, but without limiting the invention, the first binding, site may refer to the Aga2p subunit of ⁇ -agglutinin that specifically binds to the Aga1p subunit of ⁇ -agglutinin through disulfide bonds.
  • any to molecular binding partners may be used for the first binding site and the corresponding portion of the cell surface molecule.
  • Examples include Ni 2+ ions and polyhistidine tags, sugar residues and Concanavalin A, p-aminophenyl- ⁇ -D-thiogalactoside and ⁇ -galactosidase (Germino et al., Proc. Natl. Acad. Sci. USA 80 6848 (1983), glutathione and glutathione-S-transferase (Smith, D. B. and Johnson, K. S. Gene 67:311 (1988)); staphylococcal protein A and IgG (Uhlen, M. et al.
  • the term “second binding site” refers to a region of the adapter molecule that specifically recognizes and hinds the display molecule.
  • the second binding site may comprise a peptide, polypeptide, binding domain, ligand, lipid, or carbohydrate that specifically binds to a peptide, ligand, protein, lipoprotein, lipid, or carbohydrate comprising the display molecule.
  • the second binding site may refer to a PMZ domain that specifically binds to a NorpA ligand. Any of the binding pairs suitable for the first binding site may also be used for the second binding site so long as they do not recognize the same partners.
  • the term “display molecule” refers to a molecule that can be localized to the surface of the host cell via binding of the adapter molecule on the surface of the host cell.
  • the display molecule will typically comprise the molecule (or library of molecules) to be displayed and a binding partner that is specifically bound by the second binding site of the adapter molecule.
  • the molecule to be displayed and the binding partner may be one in the same.
  • the display molecule may comprise a peptide, polypeptide, binding domain, ligand, lipid, or carbohydrate or combination thereof. It should be understood that the display molecule is expressed or otherwise generated within the host cell and is secreted or excreted out of the cell so as to be displayed on the surface of said cell.
  • the display molecule may comprise a library of varied molecules that can be screened for binding to a target or for improved or altered activity.
  • the library may comprise modified polypeptides.
  • the display molecule may also comprise a tag or peptide that can be labeled so as to detect binding of the display molecule to the cell surface, or sort host cells displaying said molecule.
  • modified polypeptide refers to any polypeptide of interest that is fused to a peptide, polypeptide, binding domain, ligand, lipid, or carbohydrate that specifically binds to a peptide, ligand, protein, lipoprotein, lipid, or carbohydrate comprising the second binding site of the adapter molecule, and is displayed on the surface of the host cell (and is therefore a component of the display molecule).
  • modified polypeptide are scaffold proteins, signal transduction proteins, antibodies, immunoglobulins, immunoadhesins, receptors, ligands, oncoproteins, transcription factors, and enzymes,
  • the term “plurality of display molecules” refers to at least two copies of the display molecule displayed on the surface of host cells. In certain instances, each unique display molecule is displayed by a different host cell.
  • the term “component of the modified polypeptide” refers to any naturally occurring binding partners of any fragment of the modified peptide.
  • Non-limiting examples include an immunoglobulin light chain binding to an immunoglobulin heavy, a biotin molecule binding avidin, two subunits of ⁇ -hemoglobin dimerizing, a myosin heavy chain binding to a myosin light chain, two monomers of glycophorin. A dimerizing, or two monomers of any naturally occurring dimer protein binding to one another.
  • library of host cells refers to a plurality of host cells, wherein each host cell comprises a non-identical modified polypeptide that is displayed on the surface of the cell.
  • non-identical modified polypeptide refers to the amino acid sequence of at least two modified polypeptides, wherein each amino acid sequence comprises amino acid substitutions, insertions, or deletions which differentiate one modified polypeptide displayed on the surface of a host cell from another modified polypeptide displayed on the surface of a second host cell.
  • Fn10 refers to the tenth type III domain of human fibronectin.
  • the display molecules may be used to display any molecule that may be expressed or otherwise generated in a host cell. Non limiting examples of such molecules follow.
  • the display molecules may be immunoglobulins. Methods of generating libraries of immunoglobulins were initially developed to display the immunoglobulins via phage, but additional methods of display have since been developed. All of the methods of generating libraries for these alternative methods of display may be adapted to allow display using the methods disclosed herein. Exemplary method of generating libraries of antibodies may be found in U.S. Pat. Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al.: U.S. Pat. No 5,427,908 and 5,580,717 to Dower et al.: U.S. Pat. Nos. 5,969,108 and 6,172,197 to McCafferty et al.; and U.S. Pat. Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths et al.
  • Non-immunoglobulin frameworks or scaffolds which may be displayed using the methods disclosed herein include, but are not limited to, fibronectins (Compound Therapeutics, Inc., Waltham, Mass.), ankyrin (Molecular Partners AG, Zurich, Switzerland), domain antibodies (Domantis, Ltd (Cambridge, Mass.) and Ablynx nv (Zwijnaarde, Belgium)), lipocalin (Anticalin) (Pieris Proteolab AG, Freising, Germany), small modular immuno-pharmaceuticals (Trubion Pharmaceuticals Inc., Seattle, Wash.), maxybodies (Avidia, Inc.
  • the adnectin scaffolds are based on fibronectin type III domain (e.g., the tenth module of the fibronectin type III (10 Fn3 domain).
  • the fibronectin type III domain has 7 or 8 beta strands which are distributed between two beta sheets, which themselves pack against each other to form the core of the protein, and further containing loops (analogous to CDRs) which connect the beta strands to each other and are solvent exposed. There are at least three such loops at each edge of the beta sheet sandwich, where the edge is the boundary of the protein perpendicular to the direction of the beta strands. (U.S. Pat. No. 6,673,901).
  • fibronectin-based scaffolds are not an immunoglobulin, although the overall fold is closely related to that of the smallest functional antibody fragment, the variable region of the heavy chain, which comprises the entire antigen recognition unit in camel and llama IgG. Because of this structure, the non-immunoglobulin fibronectin molecule mimics antigen binding properties that are similar in nature and affinity to those of antibodies.
  • These scaffolds can be used in a loop randomization and shuffling strategy in vitro that is similar to the process of affinity maturation of antibodies in vivo.
  • These fibronectin-based molecules can be used as scaffolds where the loop regions of the molecule can be replaced with CDRs of the disclosure using standard cloning techniques.
  • the technology is based on using proteins with ankyrin derived repeat modules as scaffolds for bearing variable regions which can be used for binding to different targets.
  • the ankyrin repeat module is a 33 amino acid polypeptide consisting of two anti-parallel ⁇ -helices and a ⁇ -turn. Binding of the variable regions is mostly optimized by using ribosome display.
  • Avimers are derived from natural A-domain containing protein such as LRP-1. These domains are used by nature for protein-protein interactions and in human over 250 proteins art structurally based on A-domains. Avimers consist of a number of different “A-domain” monomers (2-10) linked via amino acid linkers. Avimers can be created that can bind to the target antigen using the methodology described in, for example, 20040175756; 20050053973; 20050048512; and 20060008844.
  • Affibody® affinity ligands are small, simple proteins composed of a three-helix bundle based on the scaffold of one of the IgG-binding domains of Protein A.
  • Protein A is a surface protein from the bacterium Staphylococcus aureus .
  • This scaffold domain consists of 58 amino acids, 13 of which are randomized to generate Affibody® libraries with a large number of ligand variants (See e.g., U.S. Pat. No. 5,831,012).
  • Affibody® molecules mimic antibodies, they have a molecular weight of 6 kDa, compared to the molecular weight of antibodies, which is 150 kDa. In spite of its small size, the binding site of Affibody molecules is similar to that of an antibody.
  • Anticalins® are products developed by the company Pieris ProteoLab AG. They are derived from lipocalins, a widespread group of small and robust proteins that are usually involved in the physiological transport or storage of chemically sensitive or insoluble compounds. Several natural lipocalins occur in human tissues or body liquids.
  • lipocalins are composed of a single polypeptide chain with 160 to 180 amino acid residues, being just marginally bigger than a single immunoglobulin domain.
  • the set of four loops which makes up the binding pocket, shows pronounced structural plasticity and tolerates a variety of side chains.
  • the binding site can thus be reshaped in a proprietary process in order to recognize prescribed target molecules of different shape with high affinity and specificity.
  • bilin-binding protein (BBP) of Pieris Brassicae has been used to develop anticalins by mutagenizing the set of four loops.
  • BBP bilin-binding protein
  • AffilinTM molecules are small non-immunoglobulin proteins which are designed for specific affinities towards proteins and small molecules. New AffilinTM molecules can be very quickly selected from two libraries, each of which is based on a different human derived scaffold protein.
  • AffilinTM molecules do not show any structural homology to immunoglobulin proteins.
  • Scil Proteins employs two AffilinTM scaffolds, one of which is gamma crystalline, a human structural eye lens protein and the other is “ubiquitin” superfamily proteins. Both human scaffolds are very small, show high temperature stability and are almost resistant to pH changes and denaturing agents. This high stability is mainly due to the expanded beta sheet structure of the proteins. Examples of gamma crystalline derived proteins are described in WO200104144 and examples of “ubiquitin-like” proteins are described in WO2004106368.
  • PEM are medium-sized, cyclic, peptide-like molecules (MW 1-2kDa) mimicking beta-hairpin secondary structures of proteins, the major secondary structure involved in protein-protein interactions.
  • the methods disclosed herein may be used to display any other biological molecule that can be expressed or otherwise generated in the host cell.
  • Libraries of such biological molecules, particularly polypeptides which can be encoded by polynucleotides for easy expression by the host cell may be screened for improved characteristics of interest such as improved binding between receptor and ligand where the receptor or the ligand are part of the display molecule or improved enzymatic activity where the enzyme is part of the display molecule.
  • Expression vectors may be used to express one or more of the cell surface molecules, the adapter molecule and the display molecule, in the host cell.
  • Expression vectors for eukaryotic host cells typically include (i) eukaryotic DNA elements that control initiation of transcription, such as a promoter, (ii) eukaryotic DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation signal sequence, and (iii)optionally eukaryotic DNA elements that control replication in the eukaryotic host cell if the vector is to be independently replicated (e.g., non-integrating vectors).
  • the vectors may optionally include (iv) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector when manipulating the vector in the bacterial host cell.
  • prokaryotic expression vectors for use with fungal, yeast, and mammalian cellular hosts are known in the art, and are described in, for example, Powell et al. (Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., 1985).
  • Yeast host cells are of particular interest and include Saccharomyces cerevisiae, Pichia pastoris , and Pichia methanolica . These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YEp vectors such as YEp13 and YCp vectors, such as YCp19.
  • YIp-based vectors such as YIp5
  • YRp vectors such as YRp17
  • YEp vectors such as YEp13
  • YCp vectors such as YCp19.
  • a number of vectors exist for the expression of recombinant proteins in yeast Other example of the YEp vectors include YEp24, YEp51, and YEp52,which are cloning and expression vehicles useful in the introduction of genetic constructs into S.
  • Suitable promoters for function in yeast include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255, 2073 (1980) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Req.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phospho-fructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and glucokinase.
  • Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., EP073,657.
  • yeast cloning vectors readily available and can be modified following the above discussion.
  • promoters which have the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the afore-mentioned metallothionein and glycetaldehyde-3-phosphate dehydrogenase, as well as enzymes responsible for maltose and galactose utilization.
  • promoters that are active in only one of the two haploid mating types may be appropriate in certain circumstances.
  • the pheromone promoters MFa1 and MF ⁇ 1 are of particular interest.
  • Secretion from yeast host cells of the components including the adapter molecule (if produced in the host cell) and the display molecule may be increased by use any available secretion signal sequences of yeast proteins,
  • One example is the leader sequence of a precursor of yeast mating pheromone, ⁇ -factor, which has also been used to direct secretion of heterologous proteins in yeast (See. e.g., Valenzuela, P., eds pp. 269-280, Butterworths, London; Brake, A. J. (1990) Meth. Enzymol. 185, 408-441).
  • the ⁇ -factor leader sequence in addition to the N-terminal signal peptide of 17 residues, includes a hydrophilic pro-region which contains 72 residues and bears three sites of N-linked glycosylation.
  • the pro-region is extensively glycosylated in the ER and Golgi and is cleaved by Kex2 endopeptidase in the late Golgi compartment.
  • the presence of the pro-region at the N-terminus is believed to allow some heterologous proteins to pass the quality control in the ER and to reach the periplasm.
  • leader sequence from yeast invertase (MLLQAFLFLLAGFAAKISADAHKS) (SEQ ID NO: 1). This leader sequence has been demonstrated to be cleaved from nascent heterologous peptide upon entrance into the endoplasmic reticulum.
  • the enzyme responsible for cleavage of the pre sequence, Kex2 resides in the trans Golgi.
  • signal sequence of yeast acid phosphatase which may be used to direct the secretion of the components disclosed herein.
  • Transformed cells are selected by phenotype determined by the selectable, marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine).
  • a preferred vector system for use in Saccharomyces cerevisiae is the POT1 vector system disclosed by Kawasaki et al. (U.S. Pat. No. 4,931,373), which allows transformed cells to be selected by growth in glucose containing media.
  • Transformation systems for other yeasts including Hansenula polymorpha, Schizosaccharomyces pombe, Kluyveromyces lactis, Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris, Pichia methanolica, Pichia guillermondii and Candida maltosa are known in the art. See, for example, Gleeson et al,. J. Gen. Microbiol. 132:3459 (1986), and Cregg, U.S. Pat. No. 4,882,279. Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Pat. No. 4,935,349.
  • Pichia methanolica as host for the production of recombinant proteins is disclosed by Raymond, U.S. Pat. No. 5,716,808 Raymond, U.S. Pat. No. 5,736,383, Raymond et al., Yeast 14:11-23 (1998), and in international publication Nos. WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565.
  • DNA molecules for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in P.
  • the promoter and terminator in the plasmid be that of a P. methanolica gene, such as a P. methanolica alcohol utilization gene (AUG1 or AUG2).
  • P. methanolica alcohol utilization gene AUG2
  • Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes.
  • DHAS dihydroxyacetone synthase
  • FMD formate dehydrogenase
  • CAT catalase
  • methanolica cells can be transformed by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.
  • mammalian expression vectors are also well known in the art and may be used as well.
  • suitable mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21,BHK-570; ATCC CRL8544, ATCC CRL 10314), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC (CCL61; CHO DG44 (Chasin et al., Som, Cell. Molec. Genet.
  • GH1 rat pituitary cells
  • H4-II-E rat hepatoma cells
  • COS-1 ATCC CRL 1650 SV40-transformed monkey kidney cells
  • NIH-3T3 murine embryonic cells
  • Proteins can be displayed on the surface of yeast cells by utilizing the PDZ domain of the yeast InaD protein and the C-terminal 5 amino acids of the yeast NorpA protein.
  • This three component protein display system consists of a vector expressing the protein to be displayed with a secretion signal fused at its N-terminus, and the NorpA ligand fused at the C-terminus; a second vector expressing an adapter protein that can bind specifically to a yeast cell wall protein, and which is fused to the PDZ domain of InaD, which binds specifically to the NorpA ligand; and a third vector that express a yeast cell wall protein that binds specifically to the adapter protein.
  • This system has been adapted for use in Sacchromyces cerrevisiae and Pichia pastoris.
  • the protein display system for P. pastoris was developed to display a fibronectin type 111 domain (Fn10), by fusing a hybrid secretion sequence (MFalpha/HSA) or a yeast leader sequence (MFalpha1) at N-terminus of Fn10 and fusing the NorpA ligand to its C-terminus. Once expressed, the Fn10 was secreted from the cell and the NorpA ligand bound specifically to the PDZ domain of InaD through disulfide bonds. The InaD was fused to the C-terminus of the Agap2 protein.
  • Fn10 fibronectin type 111 domain
  • MFalpha/HSA hybrid secretion sequence
  • MFalpha1 yeast leader sequence
  • the Aga2p-InaD fusion protein served as the adapter protein, and the N-terminal Aga2p bound Aga1p, which was immobilized on the surface of the cell. Aga2p bound specifically to Aga1p through disulfide bonds.
  • the three component system consisting of the Fn10-NorpA fusion protein, the
  • Aga2p-InaD fusion protein, and the Aga1p cell surface protein were cloned into pPIC expression vectors, under the control of an inducible promoter.
  • the inducible promoter used was the AOX1 promoter, which is induced by methanol.
  • AOX1 promoter which is induced by methanol.
  • the three proteins were expressed.
  • Aga1p as expressed on the surface of the cell Aga2p-InaD was localized to the cell surface where the N-terminal region of Aga2p-InaD bound to Aga1p.
  • Fn10-NorpA was localized to the secretory pathway, was secreted from the cell, and bound InaD via the C-terminal NorpA ligand ( FIG. 1 ).
  • the system can also be switched such that the InaD is fused to Aga1 and NorpA is fused to Aga2p (See FIGS. 12 and 13 ).
  • a c-myc epitope to was fused between the NorpA ligand and the C-terminus of Fn10.
  • the c-myc epitope allowed for the detection of the displayed fibronectin by using a c-myc antibody.
  • the fluorescently labeled c-myc antibody bound to the c-myc epitope on the surface of the cell was detected by fluorescence-activated cell sorting (FA(S).
  • the Escherichia coli Top10 strain (Invitrogen Carlsbad, Calif.) was used as the host strain for recombinant DNA manipulation.
  • the P. pastoris GS115 strain (Invitrogen Co., Carlsbad, Calif.) was used for the production of the fusion protein AGA2-InaD and HSA/MFalpha1-Fn10-NorpA.
  • E. coli as cultivated in LB medium (1% tryptone, 0.5% yeast extract, and 0.5% sodium chloride) containing 100 ug/mL ampicillin. P.
  • BMGY medium 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer (pH 6.0), 1.34% yeast nitrogen base, 4 ⁇ 10 ⁇ 5 % biotin, and 1% glycerol
  • BMMY medium 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer (pH 6.0), 1.34% yeast nitrogen base, 4 ⁇ 10 ⁇ 5 % biotin, and 0.5-2.0% methanol.
  • the resulting vector was named pPlC3.5-AGA1 ( FIG. 2 ).
  • the AGA2-InaD anchor gene was synthesized by Geneart (Germany) and subcloned into expression vector pPIC6a (Invitrogen) using Bst1 and EcoR1 restriction sites.
  • the resulting vector was named pPlC6-AGA2-InaD ( FIG. 4 ).
  • the fibronectin construct consists of the MFalpha1/HSA hybrid leader followed by the fibronectin fused at the C-terminus to the NorpA ligand sequence.
  • the complete gene was synthesized by Geneart (Germany) and subcloned into pPlCHOLl-1 (Mobitec).
  • the resulting vector was named pPlCHOLl-1 MFalpha1Hsa-Fn10-NorpA ( FIG. 6 ).
  • Electro-competent P. pastoris GS115 (Invitrogen) strain was prepared according to the protocol specified by the supplier and co-transformed with SalI-digested pPlC3.5-AGA1, pPlC6-AGA2-InaD. and pPlCHOLl-1 MFalpha1Hsa-Fn10-NorpA.
  • the yeast transformants were precultivated in BMGY medium containing 100 ug/ml Zeocin and 200 ug/ml Blasticidin at 30° C. for 16 hr, and used to inoculate 200 ml of BMGY medium (containing 100 ug/ml Zeocin and 200 ug/ml Balsticidin) in a 1 l baffle flask to give an initial OD 600 value of 0.1.
  • the culture was centrifuged at 1000 g for 10 min, and resuspended in BMMY medium (+100 ug/ml Zeocin and 200 ug/ml Blasticidin) containing 0.5%, 1.0%, or 2.0% methanol.
  • 100% methanol was added every 24 hr. to the culture to the final concentrations mentioned above. Analysis of displayed fibronectins on the surface of yeast is performed using FACS and anti-myc antibody.
  • fibronectin construct consisting of the MFalpha1/HSA hybrid leader followed by fibronectin fused at the C-terminus to the NorpA ligand sequence is cloned into pPlCHOLl-C instead of pPlCHOLl-1.
  • the resulting vector is named pPlCHOLl-C Mfalpha1Hsa-Fn10-NorpA ( FIG. 8 ).
  • the key difference between the two vectors is the promoter, which in pPlCHOLl-1 is the AOX1 promoter induced by methanol, and in the pPlCHOLl-C is the Cup1 promoter induced by copper.
  • AGA1 and AGA2-InaD are induced with methanol, while pPlCHOL1-C is induced with copper.
  • This allows for the capture of the secreted fibronectin on the surface of yeast mediated through the tight InaD/NorpA interaction.
  • induction with copper is sufficient. Without the induction of AGA1 and AGA2-InaD (driven by methanol) the binding partner for NorpA (AGA1/AGA2-InaD) is not present on the surface of yeast and therefore the fibronectin will be secreted.
  • This example describes using the InaD/NorpA system with other yeast strains such as Saccharomyces cerevisiae
  • Escherichia coil Top10 (Invitrogen, Carlsbad, Calif.) was used as the host strain for recombinant DNA manipulation.
  • the S. cerevisiae strain EBY100 (Invitrogen Co., Carlsbad, Calif.) was used for the production of the fusion proteins AGA2-InaD and MSalpha1/HSA-Fn10-NorpA or pYS6CT*MFalpha1-HSA-NorpA.
  • E. coli was cultivated LB medium (1% tryptone, 0.5% yeast extract, and 0.5% sodium chloride) containing 100 u/g/mL ampicillin or 100 ug/ml Blasticidin.
  • EBY 100 was cultivated in CM medium-URA.
  • the InaD anchor gene was synthesized by Geneart (Germany) and subcloned in frame with the AGA2 anchor protein into the expression vector pYD NBC1 (derivative of pYD1Invitrogen) using HindIII and EcoRI restriction sites.
  • the resulting vector was named pYD_NBC1 AGA2-InaD ( FIG. 10 ).
  • the fibronectin construct consists of the MFalpha1/HSA hybrid leader sequence followed by the fibronectin fused at its C-terminus to the NorpA ligand.
  • the complete gene was synthesized by Geneart (Germany) and subcloned into pYS6CT (Invitrogen)), in which the origin of replication had been replaced by the CEN6/ARS4 region.
  • the resulting vector was named pYS6CT_HSA_MFalpha 1 _Fn10_NorpA ( FIG. 12 ).
  • Plasmids were isolated from E. coli and the sequence confirmed. The purified plasmids were then co-transformed into EBY 100 and plated out on selective media consisting of CM-TRP, +200 ug/ml Blasticidin. Transformed colonies appeared within 2 days and were tested for display of Fibronectin by FACS analysis using an anti-myc antibody (ccccc).
  • This example describes the use of an alternative expression system, Flo1, which is used with InaD/NorpA in Pichia pastoris.
  • the Escherichia coil Top10 strain (Invitrogen Carlsbad, Calif.) is used as the host strain for recombinant DNA manipulation.
  • the P. pastoris GS115 strain (Invitrogen Co., Carlsbad, Calif.) is used for the production of the fusion protein Flo1-InaD and HSA/MFalpha1-Fn10-NorpA.
  • E. coli was cultivated in LB medium (1% tryptone, 0.5% yeast extract, and 0.5% sodium chloride) containing 100 ug/mL ampicillin. P.
  • BMGY medium 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer (pH 6.0), 1.34% yeast nitrogen base, 4 ⁇ 10 ⁇ 5 % biotin, and 1% glycerol
  • BMMY medium 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer (pH 6.0), 1.34% yeast nitrogen base, 4 ⁇ 10 ⁇ 5 % biotin, and 0.5-2.0% methanol.
  • the gene for Flo1, fused at the C-terminus to the PDZ domain of InaD is synthesized by Geneart (Germany) and cloned into pPlC3.5 (Invitrogen) using a 5′ EcoR1 site and a 3′Notl site.
  • the resulting plasmid is named pPlC3.5-Flo1-InaD.
  • Expression of the fused protein is driven by the methanol inducible promoter AOX1.
  • the fibronectin construct consists of the MFalpha1/HSA hybrid leader followed by the fibronectin fused at the C-terminus to the NorpA ligand sequence.
  • the complete gene is synthesized by Geneart (German/) and subcloned into pPlCHOLl-1 (Mobitec).
  • the resulting vector is named pP1CHOL1-1 MFalpha1Hsa-Fn10-NorpA.
  • Expression of the fibronectin construct is driven by the methanol inducible promoter AOX1.
  • Electro-competent P. pastoris GS115 (Invitrogen) strain is prepared according to the protocol specified by the supplier and co-transformed with SalI-digested pPIC3.5-Flo1-InaD, and pPlCHOLl-1 MFalpha1 Hsa-Fn10-NorpA,
  • the yeast transformants are precultivated in BMGY medium containing 100 ug/ml Zeocin and 200 ug/ml Blasticidin at 30° C. for 16 hr. and used to inoculate 200 ml of BMGY medium (containing 100 ug/ml Zeocin and 200 ug/ml Balsticidin) in a 1 l baffle flask to give an initial OD 600 value of 0.1.
  • the culture is centrifuged at 1000 g for 10 min. and resuspended in BMMY medium (+100 ug/ml Zeocin and 200 ug/ml Blasticidin) containing 0.5%, 1 or 2.0% methanol.
  • 100% methanol is added every 24 hr. to the culture to the final concentrations mentioned above. Analysis of displayed fibronectins on the surface of yeast is performed using FACS and anti-myc antibody.
  • a fibronectin library is generated by methods well known in the art, including the method disclosed in U.S. Pat. No. 6,673,901. Other methods, such as use of error prone PCR, use of random priming techniques, or use of computational techniques are well known in the art and can also be used.
  • the fibronectin library is designed with appropriate restriction enzyme cleavage sites in order to clone the library into yeast expression vectors.
  • the fibronectin library is displayed on a plurality of P. pastoris cells as described above in Example 1.
  • the fibronectin library is modified to contain an MFalpha/HSA hybrid leader sequence fused to the N-terminus and a NorpA ligand sequence fused to the C-terminus.
  • the modified fibronectin library is then cloned into the pPlCHOLl-1 vector.
  • the expression of the fibronectin library is under the control of the AOX1 promoter.
  • P. pastoris cells are transformed with the pPlCHOLl-1 vectors expressing the fibronectin library and the vectors expressing Aga1p and Aga2p-InaD. Expression of the components is induced by the addition of methanol to the cells, and the fibronectin library is displayed on a plurality of P. pastoris cells.
  • the yeast display fibronectin library is screened for binding to a target protein of interest using one of marry methods known in the an
  • the target protein is contacted with the yeast display fibronectin library under conditions that allow for the specific binding of the target protein to any members of the library. All bound target protein is no immobilized on the surface of a yeast cell. All unbound target protein is washed off.
  • the bound target protein is fluorescently labeled by methods well known in the art, such as fluorescently labeled antibodies specific for the target protein.
  • the labeled target protein, now immobilized on the surface of a yeast cell is then detected using flow cytometry, i.e. FACS.
  • yeast cells tint bind the labeled target protein will fluoresce and are sorted from those yeast cells that do not bind the target protein.
  • the sorted yeast cells that have bound the target protein are clonally expanded , and the clone line or line containing members of the fibronectin library that bind the target protein are determined.
  • a protein library is generated by methods well known in the art, such as use of error prone PCR, use of random priming techniques, or use of computational techniques.
  • the protein library is designed with appropriate restriction enzyme cleavage sites in order to clone the library into yeast expression vectors.
  • the cloned protein library is displayed on a plurality of P. pastoris cells as described above in Example 1.
  • the protein library is modified to contain an MFalpha/HSA hybrid leader sequence fused to the N-terminus and a NorpA ligand sequence fused to the C-terminus.
  • the modified protein library is then cloned into the pPlCHOLl-1 vector.
  • the expression of the protein library is tinder the control of the AOX1 promoter.
  • P. pastoris cells are transformed with the pPlCHOLl-1 vectors expressing the protein library and the vectors expressing Aga1p and Aga2p-InaD. Expression of the components is induced by the addition of methanol to the cells, and the protein library is displayed On a plurality of P. pastoris cells.
  • the yeast display protein library is screened for binding, to a target protein of interest using one of many methods known in the art.
  • the target protein is contacted with the yeast display protein library under conditions that allow for the specific binding of the target protein to any members of the library. All bound target protein is now immobilized on the surface of a yeast cell. All unbound target protein is washed off.
  • the bound target protein is fluorescently labeled by methods well known in the art, such as fluorescently labeled antibodies specific for the target protein.
  • the labeled target protein, now immobilized on the surface of a yeast cell is then detected using flow cytometry, i.e. FACS.
  • yeast cells that bind the labeled target protein will fluoresce and are sorted from those yeast cells that do not hind the target protein.
  • the sorted yeast cells that have bound the target protein are clonally expanded, and the clone line or line containing members of the protein library that bind the target protein are determined.
  • a fibronectin or HSA library is generated by methods well known in the art, such as use of error prone PCR, use of random priming techniques, or use of computational techniques.
  • the libraries are designed With appropriate restriction enzyme cleavage sites in order to clone the libraries into yeast expression vectors (See FIG. 8 and SEQ ID NO: 10).
  • the cloned fibronectin library or HSA library is displayed on a plurality of P. pastoris cells as described above in Example 1.
  • the fibronectin library is modified to contain an MFalpha/HSA hybrid leader sequence used to the N-terminus and a NorpA ligand sequence fused to the C-terminus (pYS HSA_MFalpha1 Fn10 NorpA).
  • the HSA library is modified to contain a MFalpha CT (C-Terminal) It is a left-over of the original Invitrogen vector used for the constructions. If you look at the vector map (e.g. FIG. 13 ) you can see a c-terminal v5 and 6xhis sequence of the c-terminus of the insert.
  • the modified fibronectin or HSA library is then cloned into the pYS vector.
  • the expression of the fibronectin or HSA library is under the control of the T7 promoter.
  • P. pastoris cells are transformed with the pYS vectors expressing the fibronectin or HSA library and the vectors expressing Aga1p and Aga2p-InaD, Expression of the components is induced by the addition of methanol to the cells., and, the fibronectin or HSA library is displayed on a plurality of P. pastoris cells.
  • FIGS. 9A-E Yeast cells expressing either fibronectin (pYS HSA_MFalpha1 Fn10 NorpA) or HSA (pYS6/CT HSA-NorpA) sere stained with anti-myc antibody, followed by APC labeled secondary anti-mouse antibody and then subjected to FACS analysis.
  • FIGS. 9A-E The results of the analysis are shown in FIGS. 9A-E .
  • FIG. 9A is the control sample showing unstained yeast cells
  • FIG. 9B is a sample of uninduced yeast cells expressing fibronectin
  • FIG. 9C is a sample of induced yeast cells expressing fibronectin, showing a shift of cells compared with the uninduced cells
  • FIG. 9D is a sample of uninduced yeast cells expressing HSA
  • FIG. 9E is a sample of induced yeast cells expressing HSA, again showing a shill of cells compared with the uninduced cells.
  • FIGS. 10A-E Yeast cells expressing either fibronectin (plasmid) or HSA (plasmid) were also analyzed by FMAT by staining with anti-myc antibody and APC labeled secondary anti-mouse antibody. The samples were then subjected to FMAT confocal fluorescence microscopy and shown in FIGS. 10A-E . Those colonies that express fibronectin or HSA appear as white dots against a black background. Specifically, FIG. 10A is the control sample showing unstained yeast cells and appears entirely black; FIG. 10B is a sample of uninduced yeast cells expressing fibronectin. The uninduced yeast cells do not produce fibronectin and are not detected (image appears black): FIG. 10C is a sample of induced yeast cells expressing fibronectin.
  • FIG. 10D is a sample of uninduced yeast cells expressing HSA, as before the uninduced yeast cells do not produce fibronectin and the image appears black; and FIG. 10E is a sample of induced yeast cells expressing HSA, again showing small white colonies compared with the uninduced cells.
  • a single chain scFv library is generated by methods well known in the art, such as use of error prone PCR, use of random priming techniques, or use of computational techniques.
  • the libraries are designed with appropriate restriction enzyme cleavage sites in order to clone the libraries into yeast expression vectors (See FIG. II and SEQ ID NO 11).
  • the cloned scFv lysozyme library is displayed on a plurality of P. pastoris cells as described above in Example 1.
  • the scFv library is modified to contain an MFalpha leader sequence fused to the N-terminus and a NorpA ligand sequence fused to the C-terminus (pYS6/C.T* MFalpha1-scFv lysozyme-NorpA).
  • the modified scFv lysozyme library is then cloned into the pYS vector.
  • the expression of the scFv lysozyme is under the control of the 17 promoter. P.
  • pastoris cells are transformed with the pYS vectors expressing the scFv lysozyme library and the vectors expressing Aga1p and Aga2p-InaD. Expression of the components is induced by the addition of methanol to the cells, and the fibronectin or HSA library is displayed on a plurality of P. pastoris cells.
  • Yeast cells expressing the scFv lysozyme were stained with anti-myc antibody, followed by APC labeled secondary anti-mouse antibody and then subjected to FACS analysis.
  • Yeast cells expressing the scFv lysozyme were also analyzed by FMAT by staining with anti-myc antibody and APC labeled secondary anti-mouse antibody. The samples were then subjected to FMAT confocal fluorescence microscopy.
  • yeast display system described herein is reversed such that NorpA is fused to Aga2 and the InaD is fused to Aga1.
  • a protein library is generated by methods well known in the art, such as use of error prone PCR, use of random priming techniques, or use of computational techniques.
  • the libraries are designed with appropriate restriction enzyme cleavage sites in order to clone the libraries into yeast expression vectors (See FIGS. 12 and 13 and SEQ ID NOs: 12 and 13).
  • the protein display system for P. pastoris was developed to display a fibronectin type III domain (Fn10), by fusing a leader sequence (MFalpha1)at N-terminus of InaD and fusing the Fn10 to its C-terminus.
  • Fn10 was secreted from the cell and the PDZ domain of InaD bound to the NorpA ligand through disulfide bonds.
  • the NorpA as fused to the C-terminus of the Agap2 protein.
  • the Aga2p-NorpA fusion protein served as the adapter protein, and the N- - terminal Aga2p bound Aga1p, which was immobilized on the surface of the cell. Aga2p bound specifically to Aga1p through disulfide bonds.
  • the three component system consisting of the Aga2p-NorpA fusion protein, the Aga1-InaD fusion protein, and the Aga1p cell surface protein were cloned into pPD and pYS expression vectors respectively, under the control of a Gal inducible promoter.
  • the inducible promoter used was the Gal1 promoter, which is induced by galactose.
  • Gal1 promoter which is induced by galactose.
  • the three proteins were expressed.
  • Aga1p as expressed on the surface of the cell.
  • Aga2p-NorpA as localized to the cell surface where the N-terminal region of Aga2p-NorpA bound to Aga1p.
  • Fn10-InaD was localized to the secretory pathway, Was secreted front the cell, and bound NorpA via the C-terminal InaD ligand.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US13/139,332 2008-12-16 2009-12-14 Yeast Display Systems Abandoned US20110275535A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/139,332 US20110275535A1 (en) 2008-12-16 2009-12-14 Yeast Display Systems

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12291008P 2008-12-16 2008-12-16
US13/139,332 US20110275535A1 (en) 2008-12-16 2009-12-14 Yeast Display Systems
PCT/EP2009/067066 WO2010069913A1 (en) 2008-12-16 2009-12-14 Yeast display systems

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/067066 A-371-Of-International WO2010069913A1 (en) 2008-12-16 2009-12-14 Yeast display systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/135,438 Continuation US10041064B2 (en) 2008-12-16 2016-04-21 Yeast display systems

Publications (1)

Publication Number Publication Date
US20110275535A1 true US20110275535A1 (en) 2011-11-10

Family

ID=42115977

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/139,332 Abandoned US20110275535A1 (en) 2008-12-16 2009-12-14 Yeast Display Systems
US15/135,438 Active 2030-07-18 US10041064B2 (en) 2008-12-16 2016-04-21 Yeast display systems
US16/043,936 Active US10301616B2 (en) 2008-12-16 2018-07-24 Yeast display systems

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/135,438 Active 2030-07-18 US10041064B2 (en) 2008-12-16 2016-04-21 Yeast display systems
US16/043,936 Active US10301616B2 (en) 2008-12-16 2018-07-24 Yeast display systems

Country Status (11)

Country Link
US (3) US20110275535A1 (de)
EP (1) EP2379718B2 (de)
JP (1) JP5985826B2 (de)
KR (1) KR20110104052A (de)
CN (1) CN102245771B (de)
AU (1) AU2009327189B2 (de)
CA (1) CA2746840A1 (de)
EA (1) EA201100943A1 (de)
ES (1) ES2410579T5 (de)
MX (1) MX2011006483A (de)
WO (1) WO2010069913A1 (de)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8728483B2 (en) 2008-05-22 2014-05-20 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
WO2014093357A1 (en) * 2012-12-10 2014-06-19 The University Of Queensland Cell-free biofragment compositions and related systems, devices, and methods
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8969289B2 (en) 2010-05-03 2015-03-03 Bristol-Myers Squibb Company Serum albumin binding molecules
US9017655B2 (en) 2008-11-24 2015-04-28 Bristol-Myers Squibb Company Bispecific EGFR/IGFIR binding molecules
US9234028B2 (en) 2008-02-14 2016-01-12 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US9328157B2 (en) 2003-12-05 2016-05-03 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US9416170B2 (en) 2011-10-31 2016-08-16 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US10113164B2 (en) 2013-12-23 2018-10-30 Research Corporation Technologies, Inc. Pichia pastoris surface display system
US10221232B2 (en) 2006-11-22 2019-03-05 Bristol-Myers Squibb Company Methods of treating cancer by administering IGF-IR binding molecules
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
US10787498B2 (en) 2013-02-06 2020-09-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
US10898538B2 (en) 2011-05-17 2021-01-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US11447538B2 (en) 2013-02-01 2022-09-20 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2024123891A1 (en) * 2022-12-07 2024-06-13 The University Of North Carolina At Chapel Hill Office Of Technology Commercialization Engineered microorganism compositions and applications thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012092323A1 (en) * 2010-12-28 2012-07-05 Xoma Technology Ltd. Cell surface display using pdz domains
CN102276703B (zh) * 2011-07-29 2013-09-25 华南理工大学 毕赤酵母壁蛋白Gcw51及其表面展示***和构建方法
CN102260335B (zh) * 2011-07-29 2013-09-25 华南理工大学 毕赤酵母壁蛋白Gcw3及其表面展示***和构建方法
CN102276702B (zh) * 2011-07-29 2013-09-25 华南理工大学 毕赤酵母壁蛋白Gcw30及其表面展示***和构建方法
CN102276707B (zh) * 2011-07-29 2013-09-25 华南理工大学 毕赤酵母壁蛋白Gcw19及其表面展示***和构建方法
SI2692865T1 (sl) 2012-07-30 2015-03-31 Nbe-Therapeutics Llc Technology Parc Basel S transpozicijo posredovana identifikacija specifičnih vezavnih ali funkcionalnih proteinov
CN103834630A (zh) * 2014-01-17 2014-06-04 中国药科大学 一种制备重组牛肠激酶催化亚基的方法
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
CN110268108B (zh) * 2016-12-12 2022-09-06 埃克切拉生物科学公司 用于使用微毛细管阵列进行筛选的方法和***
JP6839424B2 (ja) 2016-12-27 2021-03-10 国立大学法人 鹿児島大学 真菌におけるタンパク質の選択的分泌技術
JP7194112B2 (ja) * 2017-03-13 2022-12-21 ラレマンド ハンガリー リクィディティー マネジメント エルエルシー 細胞結合型異種タンパク質を発現する組換え酵母宿主細胞
EP3601558A4 (de) * 2017-03-24 2021-01-06 Lankenau Institute for Medical Research Verfahren und zusammensetzungen zur induzierbaren extrazellulären membranaufnahme von monoklonalen immunglobulinen, die von hybridomen abgesondert werden
CN113544275A (zh) * 2019-03-05 2021-10-22 信达生物制药(苏州)有限公司 展示与分泌目的多肽的酵母展示***及其用途
CN111378676B (zh) * 2020-02-28 2021-08-20 武汉华美生物工程有限公司 一种pCUP1载体质粒的构建及其应用
ES2955461A1 (es) 2022-05-24 2023-12-01 Univ Valencia Politecnica Levadura y plasmido para la exposicion de proteinas en superficie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0768377A1 (de) 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU8740491A (en) 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
ES2124203T3 (es) 1991-03-01 2004-04-16 Dyax Corp. Inhibidores de la elastasa neutrofila humana y la catepsina g humana.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
ES2196009T3 (es) 1992-07-08 2003-12-16 Unilever Nv Procedimiento para inmovilizar enzimas en la pared celular de una celula microbiana mediante la produccion de una proteina de fusion.
ZA94916B (en) 1993-02-10 1995-08-10 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
AU1158297A (en) 1995-11-09 1997-05-29 Zymogenetics Inc. Production of gad65 in methylotrophic yeast
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
CN1238806A (zh) 1996-07-17 1999-12-15 津莫吉尼蒂克斯公司 甲醇毕赤酵母营养突变体的制备
CA2261151C (en) 1996-07-17 2003-09-16 Zymogenetics, Inc. Transformation of pichia methanolica
EP0985039B1 (de) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1137941B2 (de) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7422860B2 (en) * 2001-02-07 2008-09-09 Massachusetts Institute Of Technology Optoelectronic detection system
DE60230128D1 (de) 2001-04-19 2009-01-15 Kansai Chem Eng Protein, das sich an die zelloberflächenschichten bindet, und dessen verwendung
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
EP1438400B1 (de) 2001-10-01 2009-06-17 Dyax Corp. Mehrkettige eukaryontische display-vektoren und deren verwendungen
US7309575B2 (en) 2002-01-16 2007-12-18 The University Of North Carolina At Chapel Hill Protein purification and detection methods
AU2003209059A1 (en) 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP2021795A4 (de) 2006-05-04 2009-05-13 Abmaxis Inc Kreuz-spezies- und multi-spezies-präsentierungssysteme
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
US8470332B2 (en) * 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
EP2137308B1 (de) † 2007-03-26 2016-08-03 Agenus Inc. Zelloberflächenpräsentation, screening und produktion von interessierenden proteinen
CN101707882A (zh) * 2007-04-17 2010-05-12 伊姆克罗尼责任有限公司 PDGFRβ特异性抑制剂
WO2008143954A2 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Daly, Rachel and Milton T. W. Hearn, "Expression of heterologous protein in Pichia pastoria: a useful experimental tool in protein engineering and production," 2005, Journal of Molecular Recognition, 18, 119-138. *
Fuh, Germaine et al., "Analysis of PDZ Domain-Ligand Interactions Using Carboxyl-terminal Phage Display," 14 July 2000, The Journal of Biological Chemistry, Vol. 275, No. 28, pages 21486-21491. *
Kimple, Michelle E., et al., "Affinity Tag for Protein Purification and Detection Based on the Disulfide-Linked Complex of InaD and NorpA," September 2002, Biotechniques, 33, pages 578-590. *
Lipovsek, Dasa et al, 2007 J. Mol. Biol. 368: 1024-1041. *
pYD1 Yeast Display Vector Kit. Manual [online]. Invitrogen, 10 December 2002 [retrieved on 11 April 2013]. Retrieved from the Internet: <URL:http://www.yrbio.com/bioresource/sites/yrbio.com.bioresource/files/document/vector/1085/pyd1_man.pdf>. *
Rakestraw, J. Andy et al, 2006 Biotechnol. Prog. 22: 1200-1208. *
Skerra, Arne, "Alternative non-antibody scaffolds for molecular recognition," 2007, Current Opinion in Biotechnology, 18, pages 295-304. *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995131B2 (en) 2003-12-05 2021-05-04 Bristol-Myers Squibb Company Libraries of modified fibronectin type III tenth domain-containing polypeptides
US9862758B2 (en) 2003-12-05 2018-01-09 Bristol-Myers Quibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US9328157B2 (en) 2003-12-05 2016-05-03 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US11149077B2 (en) 2006-11-22 2021-10-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US10221232B2 (en) 2006-11-22 2019-03-05 Bristol-Myers Squibb Company Methods of treating cancer by administering IGF-IR binding molecules
US9920108B2 (en) 2008-02-14 2018-03-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US10781247B2 (en) 2008-02-14 2020-09-22 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US9234028B2 (en) 2008-02-14 2016-01-12 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US10774130B2 (en) 2008-05-22 2020-09-15 Bristol-Myers Squibb Company Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
US9902762B2 (en) 2008-05-22 2018-02-27 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8728483B2 (en) 2008-05-22 2014-05-20 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US10954286B2 (en) 2008-11-24 2021-03-23 Bristol-Myers Squibb Company Bispecific EGFR/IGFIR binding molecules
US10183987B2 (en) 2008-11-24 2019-01-22 Bristol-Myers Squibb Company Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules
US9017655B2 (en) 2008-11-24 2015-04-28 Bristol-Myers Squibb Company Bispecific EGFR/IGFIR binding molecules
US9771411B2 (en) 2008-11-24 2017-09-26 Bristol-Myers Squibb Company Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules
US10221438B2 (en) 2010-05-03 2019-03-05 Bristol-Myers Squibb Company Serum albumin binding molecules
US9540424B2 (en) 2010-05-03 2017-01-10 Bristol-Myers Squibb Company Serum albumin binding molecules
US10934572B2 (en) 2010-05-03 2021-03-02 Bristol-Myers Squibb Company Serum albumin binding molecules
US8969289B2 (en) 2010-05-03 2015-03-03 Bristol-Myers Squibb Company Serum albumin binding molecules
US10273286B2 (en) 2010-05-26 2019-04-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US11161893B2 (en) 2010-05-26 2021-11-02 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US10214579B2 (en) 2011-04-13 2019-02-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US10898538B2 (en) 2011-05-17 2021-01-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US11279751B2 (en) 2011-10-31 2022-03-22 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US10604556B2 (en) 2011-10-31 2020-03-31 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US11408093B2 (en) 2011-10-31 2022-08-09 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9416170B2 (en) 2011-10-31 2016-08-16 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9765132B2 (en) 2011-10-31 2017-09-19 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US10464995B2 (en) 2011-10-31 2019-11-05 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US10406212B2 (en) 2012-09-13 2019-09-10 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US11813315B2 (en) 2012-09-13 2023-11-14 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8993265B2 (en) 2012-09-13 2015-03-31 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US9662373B2 (en) 2012-09-13 2017-05-30 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US9493546B2 (en) 2012-09-13 2016-11-15 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US10245302B2 (en) 2012-09-13 2019-04-02 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8933199B2 (en) 2012-09-13 2015-01-13 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US11105802B2 (en) 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
WO2014093357A1 (en) * 2012-12-10 2014-06-19 The University Of Queensland Cell-free biofragment compositions and related systems, devices, and methods
US11447538B2 (en) 2013-02-01 2022-09-20 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US10787498B2 (en) 2013-02-06 2020-09-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
US11512124B2 (en) 2013-02-06 2022-11-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US11345722B2 (en) 2013-02-12 2022-05-31 Bristol-Myers Squibb Company High pH protein refolding methods
US10113164B2 (en) 2013-12-23 2018-10-30 Research Corporation Technologies, Inc. Pichia pastoris surface display system
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
US11203630B2 (en) 2014-03-20 2021-12-21 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
US11434275B2 (en) 2015-09-23 2022-09-06 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
WO2024123891A1 (en) * 2022-12-07 2024-06-13 The University Of North Carolina At Chapel Hill Office Of Technology Commercialization Engineered microorganism compositions and applications thereof

Also Published As

Publication number Publication date
EP2379718A1 (de) 2011-10-26
EA201100943A1 (ru) 2012-05-30
ES2410579T5 (es) 2021-10-04
US20170081657A1 (en) 2017-03-23
ES2410579T3 (es) 2013-07-02
CN102245771B (zh) 2013-04-10
MX2011006483A (es) 2011-07-13
CA2746840A1 (en) 2010-06-24
KR20110104052A (ko) 2011-09-21
CN102245771A (zh) 2011-11-16
JP2012511920A (ja) 2012-05-31
US10301616B2 (en) 2019-05-28
EP2379718B1 (de) 2013-03-20
WO2010069913A1 (en) 2010-06-24
US10041064B2 (en) 2018-08-07
AU2009327189A1 (en) 2011-06-30
US20180334667A1 (en) 2018-11-22
AU2009327189B2 (en) 2012-09-06
EP2379718B2 (de) 2020-12-30
JP5985826B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
US10301616B2 (en) Yeast display systems
US11913137B2 (en) Methods for the selection of binding proteins
JP5754135B2 (ja) 関心対象のタンパク質の細胞表面ディスプレイ、スクリーニング、および産生
US20100075326A1 (en) Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
US10988759B2 (en) High throughput protein-protein interaction screening in yeast liquid culture
JP2013517761A (ja) 酵母細胞の表面上にポリペプチドをディスプレイするための方法および組成物
US8637435B2 (en) Eukaryotic cell display systems
JP2010227114A (ja) 多重鎖真核ディスプレイベクターとその使用
US20170205421A1 (en) Synthetic yeast agglutination
US20180037898A1 (en) Compositions and methods for expressing polypeptides on the surface of cells
WO2023051972A1 (en) Method for the generation and selection of a producer cell

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOEW, ANDREAS;REEL/FRAME:026431/0170

Effective date: 20091015

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION